An Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune Thrombocytopenia

16253NVG-2089-200OpenAn Open-label, Intra-participant Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous NVG-2089 in Participants with Immune ThrombocytopeniaNCT07095127IndustrialAdultTreatmentIIOtherBroome, CatherineGeorgetown University Medical Center; Lombardi Comprehensive Cancer CenterGUMC Medicine Hem-Onc; GUMC PFS2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>